Intermolecular interactions of antimicrobial fluoroquinolones with purified rat liver CYP1A2 studied by proton nuclear magnetic resonance spectroscopy

Xenobiotica

Volumn 26, Issue 10, 1996, Pages 1057-1066

  Mizuki, Y ^a   Yamamoto, K ^a   Yamaguchi, T ^a   Fujii, T ^a   Miyazaki, H ^a   Ohmori, H ^b  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AT 3970; CYTOCHROME P450 ISOENZYME; ENOXACIN; NORFLOXACIN; PHENACETIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME INHIBITION; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RAT;

ANIMALIA;

EID: 0029804422     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.3109/00498259609167422     Document Type: Article

References (37)

1. PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proceedings of the National Academy of Sciences, USA, 86, 7696-7700.
2. 19F Nuclear magnetic resonance as a probe of the spatial relationship between the heme iron of cytochrome P-450 and its substrate. Journal of Biological Chemistry, 264, 2649-2655.
3. DAVIS, J. D., AARONS, L., and HOUSTON, J. B., 1995, Metabolism of theophylline and its inhibition by fluoroquinolones in rat hepatic microsomes. Xenobiotica, 25, 563-573.
4. DAWSON, J. H., ANDERSSON, L. A. A., and SONO, M., 1982, Spectroscopic investigations of ferric cytochrome P-450-CAM ligand complexes. Journal of Biological Chemistry, 257, 3606-3617.
5. DISTLERATH, L. M., REILLY, P. E. B., MARTIN, M. V., DAVIS, G. G., WILKINSON, G. R., and GUENGERICH, F. P., 1985, Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry, 260, 9057-9067.
6. FUHR, U., WOLFF, T., HARDER, S., SCHYMANSKI, P., and STAIB, A. H., 1990, Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes. Drug Metabolism and Disposition, 18, 1005-1010.
7. FUHR, U., STROBL, G., MANAUT, F., ANDERS, E.-M., SÖRGEL, F., LOPEZ-DE-BRINAS, E., CHU, D. T. W., PERNET, A. G., MAHR, G., SANZ, F., and STAIB, A. H., 1993, Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Molecular Pharmacology, 43, 191-199.
8. GROHE, K. and HEITZER, H., 1987, Cycloaracylation of enamines, I. Synthesis of 4-quinolone-3-carboxylic acids. Liebigs Annalen der Chemie, 1987, 29-37.
9. GUENGERICH, F. P., DANNAN, G. A., WRIGHT, S. T., MARTIN, M. V., and KAMINSKY, L. S., 1982, Purification and characterization of liver microsomal cytochromes P-450: electrophoretric, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or β-naphthoflavone. Biochemistry, 21, 6019-6030.
10. IMAI, Y. and SATO, R., 1974, A gel-electrophoretically homogeneous preparation of cytochrome P-450 from liver microsomes of phenobarbital-pretreated rabbits. Biochemical and Biophysical Research Communications, 60, 8-14.
11. KAMATAKI, T. and KITAGAWA, H., 1973, Effects of lipid peroxidation on activities of drug-metabolizing enzymes in liver microsomes of rats. Biochemical Pharmacology, 22, 3199-3207.
12. KOGA, H., ITOH, A., MURAYAMA, S., SUZUE, S., and IRIKURA, T., 1980, Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1 ,4-dihydro-4-oxoquinoline-3-carboxylic acids. Journal of Medicinal Chemistry, 23, 1358-1363.
13. KOMORI, M., HASHIZUME, T., OHI, H., MIURA, T., KITADA, M., NAGASHIMA, K., and KAMATAKI, T., 1988, Cytochrome P-450 in human liver microsomes: high-performance liquid chromatographic isolation of three forms and their characterization. Journal of Biochemistry, 104, 912-916.
14. LAEMMLI, U. K., 1970, Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-685.
15. LESCA, P., LECOINTE, P., PAOLETTI, C., and MANSUY, D., 1978, Ellipticines as potent inhibitors of aryl hydrocarbon hydroxylase: their binding to microsomal cytochrome P450 and protective effect against benzo(a)pyrene mutagenicity. Biochemical Pharmacology, 27, 1203-1209.
16. LEWIS, D. F. V., IOANNIDES, C., and PARKE, D. V., 1986, Molecular dimensions of the substrate binding site of cytochrome P-448. Biochemical Pharmacology, 35, 2179-2185.
17. LOFT, S., OTTON, S. V., LENNARD, M. S., TUCKER, G. T., and POULSEN, H. E., 1991, characterization of metronidazole metabolism by human liver microsomes. Biochemical Pharmacology, 41, 1127-1134.
18. MATSUMOTO, J., MIYAMOTO, T., MINAMIDA, A., NISHIMURA, Y., EGAWA, H., and NISHIMURA, H., 1984, Pyridonecarboxylic acids as antibacterial agents. 2. Synthesis and structure-activity relationships of 1,6,7-trisubstituted 1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids, including enoxacin, a new antibacterial agent. Journal of Medicinal Chemistry, 27, 292-301.
19. MILDVAN, A. S. and GUPTA, R. K., 1978, Nuclear relaxation measurements of the geometry of enzyme-bound substrates and analogs. Methods in Enzymology, 49, 322-359.
20. MIYAMOTO, T., MATSUMOTO, J., CHIBA, K., EGAWA, H., SHIBAMORI, K., MINAMIDA, A., NISHIMURA, Y., OKADA, H., KATAOKA, M., FUJITA, M., HIROSE, T., and NAKANO, J., 1990, Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. Journal of Medicinal Chemistry, 33, 1645-1656.
21. MIZUKI, Y., KAMAURA, M., YAMAGUCHI, T., SEKINE, Y., and HASHIMOTO, M., 1989, Interaction of enoxacin with theophylline in rats. Arzneimittle Forschung/Drug Research, 39, 593-597.
22. MIZUKI, Y., FUJIWARA, I., and YAMAGUCHI, T., 1996, Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. Journal of Antimicrobial Chemotherapy, 37 (suppl. A), 41-55.
23. 450ecam. Biochemistry, 34, 8982-8988.
24. 5. Molecular Pharmacology, 21, 701-709.
25. OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. Journal of Biological Chemistry, 239, 2379-2385.
26. PELKONEN, O. and PUURUNEN, J., 1980, The effect of cimetidine on in vitro and in vivo microsomal drug metabolism in the rat. Biochemical Pharmacology, 29, 3075-3080.
27. PHILLIPS, A. H. and LANGDON, R. G., 1962, Hepatic triphosphopyridine nucleotide-cytochrome c reductase: isolation, characterization, and kinetic studies. Journal of Biological Chemistry, 237, 2652-2660.
28. RODRIGUES, A. D., GIBSON, G. G., IOANNIDES, C., and PARKE, D. V., 1987, Interactions of imidazole antifungal agents with purified cytochrome P-450 proteins. Biochemical Pharmacology, 36, 4277-4281.
29. SARKAR, M., POLK, R. E., GUZELIAN, P. S., HUNT, C., and KARNES, H. T., 1990, In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes. Antimicrobial Agents and Chemotherapy, 34, 594-599.
30. SARKAR, M. A., HUNT, C., GUZELIAN, P. S., and KARNES, H. T., 1992, Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metabolism and Disposition, 20, 31-37.
31. d wild type, proximal mutants, and distal mutants. Biochemistry, 30, 1490-1496.
32. SOLOMON, I., and BLOEMBERGEN, N., 1956, Nuclear magnetic interactions in the HF molecule. Journal of Chemical Physics, 25, 261-266.
33. TASSANEEYAKUL, W., BIRKETT, D. J., VERONESE, M. E., MCMANUS, M. E., TUKEY, R. H., QUATTROCHI, L. C., GELBOIN, H. V., and MINERS, J. O., 1993, Specificity of substrate and inhibitor probes for human cytochrome P450 1A1 and 1A2. Journal of Pharmacology and Experimental Therapeutics, 265, 401-407.
34. THOMAS, P. E., REIK, L. M., RYAN, D. E., and LEVIN, W., 1983, Induction of two immunochemically related rat liver cytochrome P-450 isozymes, cytochrome P-450c and P-450d, by structurally diverse xenobiotics. Journal of Biological Chemistry, 258, 4590-4598.
35. VALERO, F., DE LA TORRE, R., and SEGURA, J., 1991, Selective in-vitro inhibition of hepatic oxidative metabolism by quinolones: 7-ethoxyresorufin and caffeine as model substrates. Journal of Pharmacy and Pharmacology, 43, 17-21.
36. VAN DE STRAAT, R., DE VRIES, J., DE BOER, H. J. R., VROMANS, R. M., and VERMEULEN, N. P. E., 1987, Relationship between paracetamol binding to and its oxidation by two cytochromes P-450 isozymes - a proton nuclear magnetic resonance and spectrophotometnc study. Xenobiotica, 17, 1-9.
37. YASUKOCHI, Y. and MASTERS, B. S. S., 1976, Some properties of detergent-solubilized NADPH-cytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography. Journal of Biological Chemistry, 251, 5337-5344.